Charting a Bold Path for 2025
Exciting times are ahead for Camber Pharmaceuticals in 2025!
We are on track to launch up to 55 new generic medications, including several Day-One products, specialty drugs, and over-the-counter (OTC) medications. Additionally, we are continuing our investment in portfolio expansion, critical infrastructure, and associate development to create an even more significant impact.
To learn more, please watch this short message from Camber’s management team!
Recent articles
- NACDS TSE 2026 Event Recap
- Camber Specialty Marks First Day 1 Injectable Launch
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio